IGC Pharma Advances Alzheimer’s Trial with Strategic Colombian Partnership

India Globalization Capital (IGC Pharma) is significantly expanding the clinical development of its Alzheimer’s drug candidate, IGC-AD1. The company has broadened its trial network by adding a prominent research center in Colombia, a move aimed at enhancing the genetic diversity of its study participants and accessing specialized biomarker expertise.

The ongoing Phase 2 clinical investigation, known as the CALMA study, is evaluating IGC-AD1 for the treatment of agitation in Alzheimer’s dementia. This cannabinoid-based therapeutic is being tested in a randomized, double-blind, placebo-controlled trial design, the industry gold standard for assessing clinical efficacy.

Operational momentum continues, with patient recruitment approximately 70% complete as of February 2026. Company leadership has expressed Read more...